A critique of the double-blind clinical trial. Part 2.

  title={A critique of the double-blind clinical trial. Part 2.},
  author={Helmm Kiene},
  journal={Alternative therapies in health and medicine},
  volume={2 2},
  • Helmm Kiene
  • Published 1996 in Alternative therapies in health and medicine
The randomized, double-blind study is generally regarded as the gold standard of clinical drug trials. Bias can occur as a result of the blinding procedure itself, but discussions of this type of bias have been few and far between. This article continues with a detailed discussion of such blinding errors, which can obscure genuine drug effects and be of a sufficient magnitude as to generate false-negative results. Uncritical blinding in clinical studies should therefore be questioned. 

From This Paper

Topics from this paper.


Publications citing this paper.

The antidepressant debate and the balanced placebo trial design: an ethical analysis.

International journal of law and psychiatry • 2008
View 8 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…